April 20 (Reuters) - Shares of psychedelic drug developers rose on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews of psychedelic ...
The only drug named in Trump’s executive order is ibogaine, a psychedelic commonly used to treat depression, anxiety and PTSD ...
An executive order aims to speed up how quickly psychedelic drugs for mental illness can move through the regulatory process.
The list of products receiving FDA Commissioner priority review vouchers will grow this week to include three psychedelic drugs.
April 20 (Reuters) - Shares of psychedelic drug developers rose in premarket trading on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up ...
April 20 (Reuters) - Shares of psychedelic drug developers rose in premarket trading on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results